arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

AtaiBeckley Inc.

ATAI Health Care Biotechnology: Pharmaceutical Preparations
$7.21
▼ -2.4% Today
as of Sep 4, 16:46 ET
Last 30 days +3.07% Jul 27 → Sep 04
$7.15 $7.23 $7.31 $7.38 $7.46 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$7.33
High
$7.41
Low
$7.31
Volume
$10M
Avg Vol
$7M
Mkt Cap
$2.8B
P/E (TTM)
—
Beta
—
52w High
$7.45
52w Low
$3.27
Div Yield
—
Shares Out
$369M

Recent Press Releases & News last 60 days · 8 items

Aug 7 · 13:55 Zacks
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
Jul 22 · 13:55 Zacks
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
Jul 17 · 12:37 Proactive
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics
▸ Show all 8 press releases & news Free account →

Overview

52-week range
$3.27
$7.45
94% of range
Avg surprise (last 3)
+10.5%
Avg reaction (last 2)
+2.1%
100% positive
Latest IV / EM
55%
EM ±8.6% · $7 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.19$-0.16$-0.14$-0.11$-0.08 Actual $-0.15Est $-0.19Actual $-0.14Est $-0.12Actual $-0.08Est $-0.11Actual $-0.09 Mar/2025Jun/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-33M$-24M$-15M$-7M$2M Mar 25Jun 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.09 — — — — financials
Tue May 12, 2026Mar/2026 $-0.08 $-0.11 +27.3% +46.7% +2.7% earnings
Thu Aug 14, 2025Jun/2025 $-0.14 $-0.12 -16.7% — — earnings
Wed May 14, 2025Mar/2025 $-0.15 $-0.19 +21.1% — +1.4% earnings

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Jun 2025Mar 2025
Revenue$2M$954,000—$719,000$2M
Cost of revenue—————
Gross profit—————
Operating income$-44M$-31M—$-25M$-20M
Net income$-33M$-30M—$-28M$-26M
EPS (diluted)$-0.09$-0.08—$-0.14$-0.15

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Jun 2025Mar 2025
Cash & equivalents$169M$43M$85M——
Inventory—————
Total current assets$245M$250M$276M——
Total assets$265M$265M$293M——
Long-term debt—————
Total liabilities$88M$66M$71M——
Total equity$176M$199M$222M——

Implied volatility — last 90 days

22%85%148%211%274% Jun 07 — IV 123% · EM ±17.1%Jun 08 — IV 93% · EM ±12.3%Jun 09 — IV 87% · EM ±11.0%Jun 10 — IV 104% · EM ±12.3%Jun 11 — IV 128% · EM ±14.2%Jun 12 — IV 106% · EM ±10.8%Jun 15 — IV 98% · EM ±7.1%Jun 16 — IV 143% · EM ±8.5%Jun 17 — IV 147% · EM ±6.1%Jun 19 — IV 75% · EM ±16.6%Jun 22 — IV 75% · EM ±15.7%Jun 23 — IV 72% · EM ±14.8%Jun 24 — IV 75% · EM ±15.1%Jun 25 — IV 110% · EM ±21.6%Jun 26 — IV 148% · EM ±28.4%Jun 29 — IV 105% · EM ±18.7%Jun 30 — IV 109% · EM ±18.9%Jul 01 — IV 105% · EM ±17.5%Jul 02 — IV 95% · EM ±15.4%Jul 03 — IV 99% · EM ±15.4%Jul 06 — IV 113% · EM ±15.6%Jul 07 — IV 109% · EM ±14.5%Jul 08 — IV 112% · EM ±14.0%Jul 09 — IV 107% · EM ±12.6%Jul 10 — IV 83% · EM ±9.2%Jul 13 — IV 107% · EM ±8.9%Jul 14 — IV 225% · EM ±16.3%Jul 15 — IV 182% · EM ±10.7%Jul 16 — IV 67% · EM ±2.8%Jul 20 — IV 27% · EM ±6.3%Jul 21 — IV 24% · EM ±5.6%Jul 22 — IV 24% · EM ±5.6%Jul 23 — IV 25% · EM ±5.6%Jul 24 — IV 22% · EM ±4.9%Jul 27 — IV 27% · EM ±5.6%Jul 28 — IV 27% · EM ±5.6%Jul 29 — IV 28% · EM ±5.6%Jul 30 — IV 32% · EM ±6.3%Jul 31 — IV 29% · EM ±5.6%Aug 03 — IV 28% · EM ±4.9%Aug 04 — IV 32% · EM ±5.6%Aug 05 — IV 37% · EM ±6.3%Aug 06 — IV 39% · EM ±6.3%Aug 07 — IV 44% · EM ±6.9%Aug 10 — IV 55% · EM ±7.6%Aug 11 — IV 53% · EM ±6.9%Aug 12 — IV 50% · EM ±6.2%Aug 13 — IV 58% · EM ±6.9%Aug 14 — IV 69% · EM ±7.6%Aug 17 — IV 74% · EM ±6.2%Aug 18 — IV 152% · EM ±11.0%Aug 19 — IV 161% · EM ±9.5%Aug 20 — IV 274% · EM ±11.5%Aug 24 — IV 31% · EM ±6.4%Aug 25 — IV 38% · EM ±7.7%Aug 26 — IV 39% · EM ±7.8%Aug 27 — IV 40% · EM ±7.8%Aug 28 — IV 30% · EM ±5.8%Aug 31 — IV 42% · EM ±7.5%Sep 01 — IV 45% · EM ±7.8%Sep 02 — IV 47% · EM ±7.8%Sep 03 — IV 51% · EM ±8.2%Sep 04 — IV 55% · EM ±8.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in